Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 7478650, 7 pages
http://dx.doi.org/10.1155/2016/7478650
Research Article

Modulation of Bcl-x Alternative Splicing Induces Apoptosis of Human Hepatic Stellate Cells

Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA

Received 15 March 2016; Revised 20 June 2016; Accepted 21 June 2016

Academic Editor: Antonio Mazzocca

Copyright © 2016 Lin Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. L. Friedman, “Evolving challenges in hepatic fibrosis,” Nature Reviews Gastroenterology & Hepatology, vol. 7, no. 8, pp. 425–436, 2010. View at Publisher · View at Google Scholar
  2. V. Hernandez-Gea and S. L. Friedman, “Pathogenesis of liver fibrosis,” Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 425–456, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. Y.-S. Lim and W. R. Kim, “The global impact of hepatic fibrosis and end-stage liver disease,” Clinics in Liver Disease, vol. 12, no. 4, pp. 733–746, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Schuppan and Y. O. Kim, “Evolving therapies for liver fibrosis,” Journal of Clinical Investigation, vol. 123, no. 5, pp. 1887–1901, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Singh, A. M. Allen, Z. Wang, L. J. Prokop, M. H. Murad, and R. Loomba, “Fibrosis progression in nonalcoholic fatty liver vs Nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies,” Clinical Gastroenterology and Hepatology, vol. 13, no. 4, pp. 643–654, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Cohen-Naftaly and S. L. Friedman, “Current status of novel antifibrotic therapies in patients with chronic liver disease,” Therapeutic Advances in Gastroenterology, vol. 4, no. 6, pp. 391–417, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. D. C. Rockey, “Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies,” Clinical Gastroenterology and Hepatology, vol. 11, no. 3, pp. 224–231.e5, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Yin, K. J. Evason, K. Asahina, and D. Y. R. Stainier, “Hepatic stellate cells in liver development, regeneration, and cancer,” Journal of Clinical Investigation, vol. 123, no. 5, pp. 1902–1910, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. R. G. Gieling, A. D. Burt, and D. A. Mann, “Fibrosis and cirrhosis reversibility—molecular mechanisms,” Clinics in Liver Disease, vol. 12, no. 4, pp. 915–937, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. A. Gonzalez, M. I. Fiel, J. Sauk et al., “Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection,” Journal of Viral Hepatitis, vol. 16, no. 2, pp. 141–148, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. De Minicis, C. Candelaresi, L. Agostinelli et al., “Endoplasmic Reticulum stress induces hepatic stellate cell apoptosis and contributes to fibrosis resolution,” Liver International, vol. 32, no. 10, pp. 1574–1584, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Kong, F. Zhang, Z. Zhang, Y. Lu, and S. Zheng, “Clearance of activated stellate cells for hepatic fibrosis regression: molecular basis and translational potential,” Biomedicine and Pharmacotherapy, vol. 67, no. 3, pp. 246–250, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. A. M. Elsharkawy, F. Oakley, and D. A. Mann, “The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis,” Apoptosis, vol. 10, no. 5, pp. 927–939, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Novo, F. Marra, E. Zamara et al., “Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans,” Gut, vol. 55, no. 8, pp. 1174–1182, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. J. M. Adams and S. Cory, “Bcl-2-regulated apoptosis: mechanism and therapeutic potential,” Current Opinion in Immunology, vol. 19, no. 5, pp. 488–496, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Akgul, D. A. Moulding, and S. W. Edwards, “Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications,” Cellular and Molecular Life Sciences, vol. 61, no. 17, pp. 2189–2199, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. L. H. Boise, M. González-García, C. E. Postema et al., “bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death,” Cell, vol. 74, no. 4, pp. 597–608, 1993. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Yang and S. J. Korsmeyer, “Molecular thanatopsis: a discourse on the BCL2 family and cell death,” Blood, vol. 88, no. 2, pp. 386–401, 1996. View at Google Scholar · View at Scopus
  19. J.-J. Shieh, K.-T. Liu, S.-W. Huang, Y.-J. Chen, and T.-Y. Hsieh, “Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells,” Journal of Investigative Dermatology, vol. 129, no. 10, pp. 2497–2506, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Kole, A. R. Krainer, and S. Altman, “RNA therapeutics: beyond RNA interference and antisense oligonucleotides,” Nature Reviews Drug Discovery, vol. 11, no. 2, pp. 125–140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. J. A. Bauman, S.-D. Li, A. Yang, L. Huang, and R. Kole, “Anti-tumor activity of splice-switching oligonucleotides,” Nucleic Acids Research, vol. 38, no. 22, pp. 8348–8356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Zammarchi, E. De Stanchina, E. Bournazou et al., “Antitumorigenic potential of STAT3 alternative splicing modulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 43, pp. 17779–17784, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Cirak, V. Arechavala-Gomeza, M. Guglieri et al., “Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study,” The Lancet, vol. 378, no. 9791, pp. 595–605, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Zhang, J. J. Peairs, P. Yang et al., “The importance of Bcl-xL in the survival of human RPE cells,” Investigative Ophthalmology and Visual Science, vol. 48, no. 8, pp. 3846–3853, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Martín-Vílchez, P. Sanz-Cameno, Y. Rodríguez-Muñoz et al., “The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells,” Hepatology, vol. 47, no. 6, pp. 1872–1883, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Hozawa, T. Nakamura, M. Nakano et al., “Induction of matrix metalloproteinase-1 gene transcription by tumour necrosis factor α via the p50/p50 homodimer of nuclear factor-κ B in activated human hepatic stellate cells,” Liver International, vol. 28, no. 10, pp. 1418–1425, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. D. R. Mercatante, C. D. Bortner, J. A. Cidlowski, and R. Kole, “Modification of alternative splicing of Bcl-x Pre-mRNA in prostate and breast cancer cells: analysis of apoptosis and cell death,” Journal of Biological Chemistry, vol. 276, no. 19, pp. 16411–16417, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Mazzocca, S. C. Sciammetta, V. Carloni et al., “Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells,” Journal of Biological Chemistry, vol. 280, no. 12, pp. 11329–11339, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. R. J. Youle and A. Strasser, “The BCL-2 protein family: opposing activities that mediate cell death,” Nature Reviews Molecular Cell Biology, vol. 9, no. 1, pp. 47–59, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Wong, N. Tan, J. Zha et al., “Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models,” Molecular Cancer Therapeutics, vol. 11, no. 4, pp. 1026–1035, 2012. View at Google Scholar
  31. S. A. Amundson, T. G. Myers, D. Scudiero, S. Kitada, J. C. Reed, and A. J. Fornace, “An informatics approach identifying markers of chemosensitivity in human cancer cell lines,” Cancer Research, vol. 60, no. 21, pp. 6101–6110, 2000. View at Google Scholar · View at Scopus
  32. M. Van De Bovenkamp, G. M. M. Groothuis, D. K. F. Meijer, and P. Olinga, “Liver fibrosis in vitro: cell culture models and precision-cut liver slices,” Toxicology in Vitro, vol. 21, no. 4, pp. 545–557, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. D. R. Mercatante, J. L. Mohler, and R. Kole, “Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents,” The Journal of Biological Chemistry, vol. 277, no. 51, pp. 49374–49382, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. S.-D. Li and L. Huang, “Pharmacokinetics and biodistribution of nanoparticles,” Molecular Pharmaceutics, vol. 5, no. 4, pp. 496–504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Poelstra, J. Prakash, and L. Beljaars, “Drug targeting to the diseased liver,” Journal of Controlled Release, vol. 161, no. 2, pp. 188–197, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. X. Ming, “Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis,” Expert Opinion on Drug Delivery, vol. 8, no. 4, pp. 435–449, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. X. Ming and B. Laing, “Bioconjugates for targeted delivery of therapeutic oligonucleotides,” Advanced Drug Delivery Reviews, vol. 87, pp. 81–89, 2015. View at Publisher · View at Google Scholar · View at Scopus